Literature DB >> 34368661

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.

Peter J Hotez1, Carolina Batista2, Yanis Ben Amor3, Onder Ergonul4, J Peter Figueroa5, Sarah Gilbert6, Mayda Gursel7, Mazen Hassanain8, Gagandeep Kang9, David C Kaslow10, Jerome H Kim11, Bhavna Lall12, Heidi Larson13, Denise Naniche14, Timothy Sheahan15, Shmuel Shoham16, Annelies Wilder-Smith13,17,18, Samba O Sow19,20, Nathalie Strub-Wourgaft21, Prashant Yadav22,23,24, Maria Elena Bottazzi1.   

Abstract

A Lancet Commission for COVID-19 task force is shaping recommendations to achieve vaccine and therapeutics access, justice, and equity. This includes ensuring safety and effectiveness harmonized through robust systems of global pharmacovigilance and surveillance. Global production requires expanding support for development, manufacture, testing, and distribution of vaccines and therapeutics to low- and middle-income countries (LMICs). Global intellectual property rules must not stand in the way of research, production, technology transfer, or equitable access to essential health tools, and in context of pandemics to achieve increased manufacturing without discouraging innovation. Global governance around product quality requires channelling widely distributed vaccines through WHO prequalification (PQ)/emergency use listing (EUL) mechanisms and greater use of national regulatory authorities. A World Health Assembly (WHA) resolution would facilitate improvements and consistency in quality control and assurances. Global health systems require implementing steps to strengthen national systems for controlling COVID-19 and for influenza vaccinations for adults including pregnant and lactating women. A collaborative research network should strive to establish open access databases for bioinformatic analyses, together with programs directed at human capacity utilization and strengthening. Combating anti-science recognizes the urgency for countermeasures to address a global-wide disinformation movement dominating the internet and infiltrating parliaments and local governments.
© 2021 The Authors.

Entities:  

Keywords:  COVID-19; Health equity; Vaccine distribution; global governance; public health justice; public health security; therapeutics; vaccine access; vaccine development; vaccine technologies

Year:  2021        PMID: 34368661      PMCID: PMC8330385          DOI: 10.1016/j.eclinm.2021.101053

Source DB:  PubMed          Journal:  EClinicalMedicine        ISSN: 2589-5370


  9 in total

1.  Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers.

Authors:  Mohamed Lounis; Mohammed Amir Rais; Djihad Bencherit; Hani Amir Aouissi; Adda Oudjedi; Jitka Klugarová; Andrea Pokorná; Miloslav Klugar; Abanoub Riad
Journal:  Front Public Health       Date:  2022-05-16

2.  COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study.

Authors:  Miloslav Klugar; Abanoub Riad; Lekshmi Mohanan; Andrea Pokorná
Journal:  Vaccines (Basel)       Date:  2021-12-06

Review 3.  SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.

Authors:  Stefan Pilz; Verena Theiler-Schwetz; Christian Trummer; Robert Krause; John P A Ioannidis
Journal:  Environ Res       Date:  2022-02-08       Impact factor: 8.431

Review 4.  Japan's development assistance for health: Historical trends and prospects for a new era.

Authors:  Shuhei Nomura; Lisa Yamasaki; Kazuki Shimizu; Cyrus Ghaznavi; Haruka Sakamoto
Journal:  Lancet Reg Health West Pac       Date:  2022-02-22

5.  Integrated autolysis, DNA hydrolysis and precipitation enables an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral and clinical-stage anti-COVID-19 candidate.

Authors:  John S Decker; Romel Menacho-Melgar; Michael D Lynch
Journal:  Biochem Eng J       Date:  2022-03-12       Impact factor: 3.978

6.  Towards A new model of global health justice: the case of COVID-19 vaccines.

Authors:  Nancy S Jecker; Caesar A Atuire; Susan D Bull
Journal:  J Med Ethics       Date:  2022-04-29       Impact factor: 5.926

7.  Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021-2022: A Naturalistic Case-Control Study in Sweden.

Authors:  Armin Spreco; Örjan Dahlström; Anna Jöud; Dennis Nordvall; Cecilia Fagerström; Eva Blomqvist; Fredrik Gustafsson; Jorma Hinkula; Thomas Schön; Toomas Timpka
Journal:  Vaccines (Basel)       Date:  2022-08-07

8.  Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.

Authors:  José Francisco Muñoz-Valle; Gabriela Athziri Sánchez-Zuno; Mónica Guadalupe Matuz-Flores; Cristian Oswaldo Hernández-Ramírez; Saúl Alberto Díaz-Pérez; Christian Johana Baños-Hernández; Francisco Javier Turrubiates-Hernández; Alejandra Natali Vega-Magaña; Jorge Hernández-Bello
Journal:  Vaccines (Basel)       Date:  2022-03-05

Review 9.  Global Health Governance and Health Equity in the Context of COVID-19: A Scoping Review.

Authors:  Wafa Abu El Kheir-Mataria; Hassan El-Fawal; Shahjahan Bhuiyan; Sungsoo Chun
Journal:  Healthcare (Basel)       Date:  2022-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.